Host-Directed Therapeutics for the Prevention of Progression to ARDS
BARDA seeks to advance the late-stage clinical development of host-directed therapeutics that can prevent hospitalized patients with severe viral respiratory infections from progressing to acute respiratory distress syndrome (ARDS). By addressing a critical gap where antiviral treatment alone may be insufficient, the effort aims to reduce severe outcomes and strengthen national preparedness for seasonal and pandemic respiratory threats.
Tozorakimab - Development of an anti-IL33 mAb for the prevention of progression to ARDS
Project Objective: The project’s objective is to support the Phase III TILIA trial in evaluating whether tozorakimab, added to standard care, is safe and effective for patients hospitalized with viral lung infections who require supplemental oxygen. Specifically, the trial aims to determine whether targeting IL-33–mediated inflammation can prevent death or progression to invasive mechanical ventilation or extracorporeal membrane oxygenation.
Project Details
Member Organization: AstraZeneca Pharmaceuticals LP
Award Date: 09/29/2026
Award Amount: $48,384,562
Project Duration: 29 Months
Solicitation Number: RRPV RPP-26-12-ARDS